Lavipharm S.A. (ATSE:LAVI) entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi (ENXTPA:SAN) on December 11, 2023. Commercialization of the product by Lavipharm is expected to take place upon completion of the relevant marketing authorization transfer, during Q2 of 2024. On an annual basis, the product has generated historical sales of approximately ?1.4 million (Wholesale Prices) in Greece.

The transaction will be financed by the company's own funds.